Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial

PURPOSE: We hypothesized that the addition of gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, to docetaxel would enhance therapeutic efficacy in squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS: Patients with recurrent or metastatic SCCHN wi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Argiris, Athanassios, Ghebremichael, Musie, Gilbert, Jill, Lee, Ju-Whei, Sachidanandam, Kamakshi, Kolesar, Jill M., Burtness, Barbara, Forastiere, Arlene A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2013
Schlagworte:
ORIGINAL REPORTS
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3612594/
https://ncbi.nlm.nih.gov/pubmed/23460714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.45.4272
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge